Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...

Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

At Least $4 Billion Anticipated by End of 2024 from Cost Realignment Program(5) Approximately $1.5 Billion Expected by End of 2027 from First Phase of Manufacturing Optimization Program Pfizer Inc ...